Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lundbeck to further examine Lu AA21004

Lundbeck to further examine Lu AA21004

9th June 2009

Lundbeck still needs to establish what the most appropriate dose of Lu AA21004 is.

Along with Takeda, the company is investigating the drug’s ability to treat major depressive disorder (MDD).

Previous phase II studies showed five and ten milligram doses had the same efficacy.

A more recent phase III trial has not found any significant difference between 2.5 and five milligrams, compared to the placebo.

The latest study discovered five and ten milligrams have a greater effect than the placebo and that higher doses may be more efficacious overall.

Although further studies are required to work out how much Lu AA21004 is needed to have the most benefit for patients, all investigations to date have shown the medication to be well tolerated and safe.

The therapy ? which will be examined further for MDD – is also being analysed for its effect on sufferers of generalised anxiety disorder.

In April this year, Lundbeck received a positive opinion from the Food and Drug Administration’s Psychopharmacology Drug Advisory Committee for its medication Serdolect (sertindole) to aid patients with schizophrenia.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.